Forian Inc. has entered into a definitive merger agreement to be acquired by a consortium of investors led by Chairman and Chief Executive Officer Max Wygod, together with certain other senior executives and existing stockholders. The all-cash transaction values the company's equity at approximately $68 million and will return Forian to private ownership. Under the agreement, Forian stockholders will receive $2.17 per share in cash, representing a premium of approximately 22.6% to the company's unaffected closing price as of August 22, 2025.
The transaction was unanimously approved by the Forian Board of Directors, acting upon the unanimous recommendation of a Special Committee of disinterested and independent directors formed in response to the consortium's initial proposal. The Forian Board of Directors unanimously recommends that all stockholders tender their shares into the offer. This move is significant as it represents a strategic shift away from public market pressures, allowing the company to operate without the quarterly reporting demands and shareholder scrutiny associated with being publicly traded on the Nasdaq Stock Market.
The transaction is expected to close in the second quarter of 2026, subject to the satisfaction of the minimum tender condition and other closing conditions. Following completion, Forian will no longer be listed on the Nasdaq Stock Market or any public exchange. The company will continue to be led by Max Wygod and the current leadership team, maintaining its headquarters in Newtown, Pennsylvania and operating under the Forian name. This continuity in leadership suggests the acquisition is intended to provide operational stability and allow management to execute long-term strategies without short-term market expectations.
Forian provides data management capabilities and proprietary information and analytics solutions for customers in life sciences, healthcare, and financial services. The company has industry leading expertise in acquiring, integrating, normalizing and commercializing large-scale healthcare data assets. More information about the company is available at https://www.forian.com. The implications of this transaction extend to Forian's client base and the competitive landscape, as private ownership could facilitate more aggressive investment in its data platforms and analytics services, potentially accelerating innovation in the healthcare data sector.
Concurrent with entering into the merger agreement, consortium members have committed to provide the funding necessary to pay the cash consideration, and the transaction is not subject to a financing condition. This removes a common deal risk and increases the likelihood of the transaction closing as planned. Important documents related to the transaction will be filed with the SEC and available at https://www.sec.gov. The solicitation and offer to purchase shares will only be made pursuant to formal tender offer materials that will be filed with regulatory authorities. The deal highlights a trend of management-led buyouts in the technology and data analytics space, where executives seek greater control to navigate complex industry transformations away from public market volatility.
